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The coronavirus disease 2019 (COVID-19) pandemic is an unprece-
dented challenge. Meeting this has resulted in changes to working
practices and the impact on the management of patients with heart
failure with reduced ejection fraction (HFrEF) is largely unknown. We
performed a retrospective, observational study contrasting patients
diagnosed with HFrEF attending specialist heart failure clinics at a UK
hospital, whose subsequent period of optimisation of medical ther-
apy was during the COVID-19 pandemic, with patients diagnosed the
previous year. The primary outcome was the change in equivalent
dosing of ramipril and bisoprolol at 6-months. Secondary outcomes
were the number and type of follow-up consultations, hospitalisa-
tion for heart failure and all-cause mortality. In total, 60 patients
were diagnosed with HFrEF between 1 December 2019 and 30 April
2020, compared to 54 during the same period of the previous year.
The absolute number of consultations was higher (390 vs 270; p =
0.69), driven by increases in telephone consultations, with a reduc-
tion in appointments with hospital nurse specialists. After 6-months,
we observed lower equivalent dosing of ramipril (3.1 ± 3.0 mg vs 4.4
± 0.5 mg; p = 0.035) and similar dosing of bisoprolol (4.1± 0.5 mg vs
4.9±0.5 mg; p = 0.27), which persisted for ramipril (mean difference
1.0 mg, 95% CI 0.018–2.09; p = 0.046) and bisoprolol (mean differ-
ence 0.52 mg, 95% CI -0.23–1.28; p = 0.17) after adjustment for base-
line dosing. We observed no differences in the proportion of patients
who died (5.0% vs 7.4%; p = 0.59) or were hospitalised with heart fail-
ure (13.3% vs 9.3%; p = 0.49). Our study suggests the transition to
telephone appointments and re-deployment of heart failure nurse
specialists was associated with less successful optimisation of med-
ical therapy, especially renin-angiotensin inhibitors, compared with
usual care.
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1. Background
The coronavirus disease 2019 (COVID-19) pandemic is
an unprecedented challenge to healthcare systems. Meeting
this has resulted in dramatic changes to working practices for
those caring for patients with chronic diseases. The Leeds In-
tegrated Heart Failure service comprises of physicians, heart
failure nurse specialists and dedicated cardiac physiologists,
combining hospital and community care. A principle aim
of the service is optimising the delivery of guideline-directed
medical therapy (GDMT) to improve outcomes for patients
with heart failure [1].
The re-deployment of healthcare personnel, transition
from face-to-face to telephone consultations and the wider
impact of the COVID-19 pandemic on the management of
patients with heart failure remains largely unknown. Here
we report the changes in frequency and type of follow-up ap-
pointments, optimisation of GDMT and outcomes in newly
diagnosed patients with heart failure with reduced ejection
fraction (HFrEF) during the first wave of the pandemic.
2. Methods
2.1 Study design
Weperformed a retrospective, observational study in am-
bulatory patients with newly diagnosed HFrEF attending
the Leeds Integrated Heart Failure Service, designed and re-
ported according to the Strengthening the Reporting of Ob-
servational Studies in Epidemiology (STROBE) guidelines.
2.2 Participants
We contrasted patients diagnosed with HFrEF between 1
December 2019 and 30 April 2020 whose diagnosis and sub-
sequent period of dose optimisation of GDMT was during
the first wave of the COVID-19 pandemic, with patients di-
agnosed during the same period the previous year. Inclusion
required no previous diagnosis of HFrEF, age≥18 years and
left ventricular ejection fraction (LVEF) <50% on transtho-
racic echocardiogram. Patients who were diagnosed but died
within 6-months were excluded from the analysis but are re-
ported in Fig. 1.
2.3 Variables and data sources
We recorded patient demographics, aetiology of heart
failure, past medical history, functional capacity accord-
ing to New York Heart Associated (NYHA) classification.
Transthoracic echocardiogram was performed at the point
of first attendance at the integrated heart failure service and
we measured LVEF according to Simpson’s biplane method,
left ventricular (LV) end-diastolic diameter, right ventricular
impairment and presence of regional wall motion abnormal-
Fig. 1. Study flow chart. Description: Inclusion and exclusion criteria of patients referred to the Leeds integrated heart failure service.
ity according to national recommendations [2]. We recorded
dosing of guideline-directed medical therapy at enrolment
and at 6-months. We assessed the frequency and type of
follow-up consultations, outpatient blood tests, change in
dosing of angiotensin converting enzyme inhibitors (ACEi)
or angiotensin II receptor blockers (ARB), β-blockers and
loop diuretics.
2.4 Definitions
The date of the first echocardiogram showing LVEF
<50%was regarded as the time of diagnosis. For the purposes
of analysis, the doses of renin-angiotensin system inhibitors,
β-blockers and loop diuretics are expressed as equivalent
doses relative to the maximum licensed doses of ramipril,
bisoprolol and furosemide, respectively.
2.5 Assessment of outcomes
Patients were followed up until death or 6-months fol-
lowing diagnosis. Outcomes data were obtained from the
electronic Patient Pathway Manager Plus care record, which
updates mortality events daily directly from the UK Office
of National Statistics. The primary outcome was the change
in equivalent dosing of ramipril and bisoprolol between the
time of diagnosis and 6-months. Secondary outcomes were
the number and type of follow-up consultations, hospitali-
sation for heart failure and all-cause mortality during the 6-
month period following diagnosis.
2.6 Statistics
All statistical analyses were performed using IBM SPSS
Statistics version 26 (IBM Corporation, Armonk, NY, USA).
Unless otherwise stated, continuous variables are expressed
as mean ± SEM and discrete variables as number (percent-
ages). Groups were compared using Student’s t-test, Mann-
Whitney U test or χ2 as appropriate. Changes in dosing of
GDMT between study cohorts was compared by one-way
analysis of covariance adjusted for baseline dosing. In all anal-
yses statistical significance was defined as p< 0.05.
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3. Results
3.1 Patients
A total 60 patients were newly diagnosed with HFrEF fol-
lowing referral to the integrated heart failure service between
01 Dec 2019 and 30 April 2020, compared to 54 during the
same period in the previous year (Fig. 1). Patients had amean
age of 74.7± 1.2 years and 70 (61.4%) weremale. At baseline,
themajority of patientswere receiving a beta-blocker (70.2%)
and an ACEi/ARB (64.0%). The majority of patients were
New York Heart Association Class II (57.9%) or III (35.1%)
and the mean LVEF was 33.1 ± 1.1%. Patients were well
matched between study periods with no differences in co-
morbidities, measured parameters or dosing of medications
(Table 1).
3.2 Consultations
In the first 6-months following diagnosis the absolute
number of consultations was higher during the COVID-19
pandemic (390 vs 270; p = 0.69) compared to the previous
year (Table 2). This was primarily driven by increases in the
number telephone consultations with community heart fail-
ure nurses (185 vs 53; p = 0.008). However, the number of
consultations with hospital heart failure specialist nurses was
less, no patients were seen face-to-face (28 vs 0; p = 0.001)
and only one had telephone follow-up (3 vs 1; p = 0.26) dur-
ing the study period. Although the number of consultations
with physicians was similar, we observed a transition from
face-to-face (76 vs 61; p = 0.033), to telephone appointments
(0 vs 21; p< 0.001). Additionally, themedian number of out-
patient blood tests was less during the COVID-19 pandemic,
compared to the previous year (4 (2–6) vs 3 (1–4); p = 0.03).
3.3 Dosing of medical therapy
Equivalent doses of ramipril (3.1± 0.44 mg vs 2.7± 0.44
mg; p = 0.56) and bisoprolol (3.8 ± 0.49 mg vs 3.2 ± 0.42
mg; p = 0.35) were similar between study periods at base-
line. After 6-months we observed lower equivalent dosing
of ramipril during the pandemic compared with the previ-
ous year (3.1± 3.0 mg vs 4.4± 0.5 mg; p = 0.035), although
equivalent dosing of bisoprolol was similar (4.1 ± 0.5 mg vs
4.9± 0.5 mg; p = 0.27) (Fig. 2). These observations persisted
after adjustment for dosing at baseline, with mean difference
of equivalent dosing of ramipril of 1.0mg (95%CI 0.018–2.09;
p = 0.046) and for bisoprolol 0.52 mg (95% CI –0.23–1.28; p =
0.17) between study periods. The dosing of loop diuretic was
similar at baseline and at follow-up (mean change 18.9± 6.5
vs 11.1± 5.6 mg; p = 0.36).
3.4 Heart failure hospitalisation and survival
We observed no differences in the proportion of patients
who died (5.0% vs 7.4%; p = 0.59) or were hospitalised with
heart failure (13.3% vs 9.3%; p = 0.49) between study periods.
4. Discussion
In this retrospective analysis of newly diagnosed patients
with HFrEF referred to the Leeds Integrated Heart Failure
Service, we observed that during the COVID-19 pandemic
patients were more often managed by telephone consulta-
tions and the optimisation of GDMT, especially ACEi/ARB
was less successful compared to the previous year.
Recent reports have highlighted that patients with HFrEF
are at high-risk of severe disease from COVID-19 [3, 4], and
that the pandemic has also resulted in significant disruption
to heart failure service including the cancellation or post-
ponement of appointments and investigations [5]. Addition-
ally, reports have highlighted a reluctance to seek medical at-
tention, with reduced attendances with worsening heart fail-
ure during the peak of the pandemic [6, 7]. However, the
impact of the pandemic on the optimisation of GDMT is un-
known.
In the UK, heart failure nurse specialists supervise the
titration and optimisation of GDMT for patients proven to
have HFrEF. The majority of these specialist nurses are inde-
pendent prescribers and many have additional qualifications
in advanced practice. In many regions, including ours, the
pandemic resulted in the re-deployment of nurse specialists,
especially those working in hospital settings away from heart
failure services to manage the burden of COVID-19. Perhaps
in response to this, the number of consultations with com-
munity heart failure nurse specialists increased, albeit with a
transition to telephone consultations.
For patients with newly diagnosed HFrEF, the optimi-
sation of GDMT was less during the COVID-19 pandemic
compared to the previous year, especially the up-titration of
inhibitors of the renin-angiotensin system, despite an over-
all higher number of consultations. The reasons for this may
firstly be due to carers being less comfortable with dose es-
calation of medications which usually require an assessment
of blood pressure and kidney function between dosing in-
crements. Prior to the pandemic, usual practice was to re-
quire blood tests for renal function after two weeks, with
regular follow-up appointments to titrate dosing according
to blood pressure and heart rate. Whilst during the pan-
demic, the majority of patients had access to blood pres-
sure monitors (provided by primary care or purchased), the
access to routine blood testing was reduced. Hence, given
the more directly clinically obvious effects of β-blockers and
thereby more straightforward monitoring of side effects or
complications of therapy, may have meant carers were more
comfortable to up-titrate these agents. Additionally, the re-
deployment of hospital heart failure nurse specialists away
from heart failure services is likely to have an impact on the
optimisation of GDMT, because of their key role in patient
education and ongoing care.
We have previously shown that even small increments
in dosing of disease modifying therapies are associated with
favourable outcomes in HFrEF [8]. We explored rates of
heart failure hospitalisations and all-cause mortality, and al-
though observed outcomes were similar, this might have
been due to small numbers of patients a low event rate, and
it is feasible that at a population level, the COVID-19 pan-
demic might have resulted in worse long-term outcomes for
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Table 1. Baseline clinical characteristics of patients between study periods.
All patients (n = 114) COVID-19 (n = 60) Previous year (n = 54) p-value
Demographics
Age (years) 74.7± 1.2 74.3± 1.6 75.2± 1.7 0.72
Male sex [n (%)] 70 (61.4) 35 (58.2) 35 (64.8) 0.48
Medical history
Ischaemic aetiology [n (%)] 36 (32.4) 15 (25.4) 21 (40.4) 0.093
Hypertension [n (%)] 61 (53.5) 33 (55.0) 28 (51.9) 0.74
Diabetes mellitus [n (%)] 44 (38.6) 20 (33.3) 24 (44.4) 0.22
Atrial fibrillation [n (%)] 47 (41.2) 25 (41.7) 22 (40.7) 0.92
Stroke [n (%)] 11 (9.6) 3 (5.0) 8 (14.8) 0.076
Chronic kidney disease [n (%)] 25 (21.9) 12 (20.0) 13 (24.1) 0.60
COPD [n (%)] 14 (12.3) 6 (14.8) 8 (10.0) 0.43
NYHA class
I 8 (7.0) 6 (10.0) 2 (3.7)
II 66 (57.9) 36 (60.0) 30 (55.6) 0.27
III 40 (35.1) 18 (30.0) 22 (40.7)
Blood tests
Haemoglobin (g/L) 128.7± 1.8 129.5± 2.2 127.8± 3.0 0.64
Creatinine (µmol/L) 100.1± 3.6 98.4± 5.0 102.0± 5.3 0.61
Albumin (g/L) 35.7± 0.4 35.5± 0.6 35.9± 0.6 0.66
HbA1c (mmol/mol) 47.7± 1.4 46.0± 1.4 49.7± 2.5 0.21
NT-pro-BNP (ng/L) 6577.9± 681.6 6620.6± 856.7 6526.1± 1103.7 0.95
Electrocardiogram
Heart rate (beats/min) 83.2± 1.9 85.1± 2.5 81.3± 2.9 0.33
QRS (ms) 109.5± 2.5 105.5± 3.3 113.6± 3.7 0.10
PR (ms) 181.1± 5.4 174.4± 7.6 188.8± 7.6 0.19
LBBB [n (%)] 15 (13.5) 7 (12.3) 8 (14.8) 0.46
Echocardiogram
LVEF (%) 33.1± 1.1 33.8± 1.5 32.4± 1.7 0.54
LVEDd (mm) 54.4± 0.9 53.1± 1.1 56.1± 1.6 0.13
RV impairment [n (%)] 57 (50.4) 32 (54.2) 25 (46.3) 0.40
RWMA [n (%)] 70 (61.4) 32 (53.3) 38 (70.4) 0.062
Baseline medical therapy
Beta-blocker [n (%)] 80 (70.2) 42 (70.0) 38 (70.4) 0.97
Bisoprolol dose (mg) 3.5± 0.3 3.2± 0.4 3.8± 0.5 0.35
ACEi/ARB [n (%)] 73 (64.0) 36 (60.0) 37 (68.5) 0.34
Ramipril dose ( mg) 2.9± 0.3 2.7± 0.4 3.1± 0.4 0.56
Loop diuretic [n (%)] 75 (65.8) 42 (70.0) 33 (61.1) 0.32
Furosemide dose (mg) 38.0± 4.5 40.7± 6.8 35.0± 6.0 0.54
MRA [n (%)] 24 (21.1) 15 (25.0) 9 (16.7) 0.28
Ivabradine 5 (4.4) 1 (1.7) 4 (7.4) 0.14
SGLT2i [n (%)] 12 (10.5) 7 (11.7) 5 (9.3) 0.68
Antiplatelet [n (%)] 41 (36.0) 20 (33.3) 21 (38.9) 0.54
Anticoagulant [n (%)] 34 (29.8) 20 (33.3) 14 (25.9) 0.39
COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association; HbA1c, glycosylated haemoglobin; NT-pro-BNP, N-
terminal pro-brain natriuretic peptide; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVEDd, left ventricular end-
diastolic diameter; RV, right ventricular; RWMA, regional wall motion abnormality; ACEi, angiotensin converting enzyme inhibitor; ARB,
angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium-glucose co-transporter 2 inhibitor.
patients with HFrEF and this warrants further investiga-
tion. Another explanation might be due to a reluctance to
seek medical attention, as evidenced by the lower rate of at-
tendances for worsening heart failure observed during the
COVID-19 pandemic [6, 9].
The principal limitations of this study are the small sample
size and short duration of follow-up. Despite this, we were
able to show a less successful optimisation of medical ther-
apies during the COVID-19 pandemic. This study was con-
ducted in a single centre in theUK, and somaynot be general-
isable to other healthcare systems. We included patients who
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Fig. 2. Plots of the change in equivalent dosing of ramipril and bisoprolol between baseline and 6-months, excluding patientswhowere receiv-
ing maximum licensed doses at baseline. Description: The change in dosing was lower for patients whose period of dose optimisation was during the
COVID-19 pandemic. * p< 0.05.
Table 2. Frequency of follow-up consultations during the
study periods.
COVID-19 Previous year p-value
Hospital nurse face-to-face 0 28 0.001
Hospital nurse telephone 1 3 0.26
Community nurse face-to-face 122 110 0.50
Community nurse telephone 185 53 0.008
Physician face-to-face 61 76 0.003
Physician telephone 21 0 <0.001
had LVEF 40–49% who might be regarded as having heart
failure with mid-range ejection fraction according to guide-
lines [1]. Despite there being less clear-cut evidence of ben-
efit of medical therapy for such patients, it is usual practice
that those presenting with signs and symptoms of heart fail-
ure, with raised NT-proBNP and evidence of LV systolic dys-
function to be treated with an ACEi/ARB and beta-blocker.
5. Conclusions
Our study adds to the growing literature of the impact
of the COVID-19 pandemic on the care for patients with
chronic heart failure [6]. Our data suggest that a transition
towards telephone consultations and reduction in appoint-
ments with hospital heart failure nurses was associated with
less successful optimisation of GDMT compared to usual care
involving face-to-face clinics, with implications for service
design during subsequentwaves of the pandemic and beyond.
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